Biomx Inc's Business Segments

The company is a clinical-stage product discovery firm focused on developing phage-based therapies targeting harmful bacteria associated with chronic diseases such as diabetic foot infections (DFI). Its proprietary platform employs natural and engineered bacteriophages—species-specific viruses that infect and kill bacteria without affecting mammalian cells. The company offers two types of phage therapies: fixed cocktail therapy, which uses a single product containing a fixed number of phages to address a broad range of bacterial strains, and personalized therapy, which matches optimal phages from a large library to individual patients through proprietary susceptibility testing. The platform integrates computational biology, microbiology, synthetic engineering, and manufacturing to develop optimized phage cocktails with broad host range, resistance prevention, biofilm penetration, and stability. In December 2025, the company discontinued development of its cystic fibrosis phage cocktail, BX004, due to adverse events and resource limitations, resulting in insolvency proceedings for its Israeli subsidiary, BiomX Ltd. Current main programs include BX011, a fixed multi-phage cocktail targeting Staphylococcus aureus in DFI, and BX211, a personalized phage therapy for diabetic foot osteomyelitis (DFO) associated with S. aureus. BX211 demonstrated positive Phase 2 trial results in March 2025. The company has no approved products or revenue from sales and is pursuing strategic alternatives amid financial challenges.

The Company operates as a single segment focused on clinical-stage product discovery using natural and engineered phage technologies. The chief executive officer serves as the chief operating decision-maker, reviewing consolidated financial information and monitoring net loss and operating loss to assess segment performance and allocate resources. Major expenses include research and development salaries and related costs, general and administrative salaries and related costs, clinical trials, stock-based compensation, depreciation, goodwill, in-process research and development (IPR&D), impairment of long-lived assets, external professional services, rent, insurance, and other administrative expenses, net of grants received. The Company's property, equipment, and operating lease right-of-use assets are located in Israel and the United States.